Poland· PL-100410189
Kymriah
A tisagenlecleucel product containing tisagenlecleucelum, registered in Poland by Novartis Europharm Limited. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Tisagenlecleucel is registered in 11 of 19 countries.
Countries holding a registration under ATC L01XL04 (tisagenlecleucel), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 7 of them publish a price we can compare per daily dose
Tisagenlecleucel · ATC L01XL04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Japan
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
URPL (Poland)- Active substance
- Tisagenlecleucelum
- Manufacturer
- Novartis Europharm Limited
- Country
- Poland (PL)
- ATC code
- L01XL04
- ATC class
- Tisagenlecleucel
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 1
- gtin05909991384388
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Interactions
60 interactions on record for tisagenlecleucel.
Graded by severity as the source publishes them — 28 severe. Severity grades are free for everyone; mechanism and management come with Growth.
- Severity for every pair — free, no plan needed
- The source, licence and sync date on every record
- Mechanism and what to do for each pair — Growth plan
Tisagenlecleucel · interactions on record
60 records
- 28 severe
- 32 moderate
Most severe, free to view
- CladribineL01BB04severe
- Talimogene laherparepvecL01XL02severe
- Talimogen laherparepvecL01XX51severe
- LeflunomidL04AA13severe
- Interaction severity from DDInter 2.0 (Xiong G. et al., Nucleic Acids Res.), licensed CC BY-NC 4.0 — free for non-commercial use only; not covered by the Drug Database commercial licence.
Same medicine, other countries
Tisagenlecleucel in 12 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- United StatesKYMRIAHNovartis Pharmaceuticals Corporation
- FranceKYMRIAH 1,2 x 1 000 000 - 6 x 100 000 000 cellules, dispersion pour perfusionNOVARTIS EUROPHARM (IRLANDE)
- SwitzerlandKymriah, Zellsuspension zur InfusionNovartis Pharma Schweiz AG
- CzechiaKYMRIAHNovartis Europharm Limited, Dublin
- SpainKYMRIAH 1,2 x 10e6 - 6,0 x 10e8 celulas dispersion para perfusionNovartis Europharm Limited
- FinlandKymriahNovartis Europharm Limited
- BelgiumKymriah 1,2 x 10*6 – 6 x 10*8 cellsNovartis Europharm
- United KingdomKymriah 1.2million-600million cells dispersion for infusion bagsNovartis Pharmaceuticals UK Ltd
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Kymriah
- Liechtenstein · Kymriah
- Norway · Kymriah
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/ba390b97-d69f-4f71-abd6-097840d5fa7a GET /v1/drugs/ba390b97-d69f-4f71-abd6-097840d5fa7a?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Dyspersja do infuzji",
"source": "urpl",
"strength": "1,2 x 10^6 – 6 x 10^8 komórek",
"packaging": "05909991384388 ¦ Rpz ¦ EU/1/18/1297/001 ¦ 129544\n1 worek 50 ml",
"substance": "Tisagenlecleucelum 1,2 x 10^6 – 6 x 10^8 komórek",
"common_name": "Tisagenlecleucelum",
"pl_product_id": "100410189",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about tisagenlecleucel.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.